Results 231 to 240 of about 129,578 (294)

Research progress on multivalent genetically engineered vaccines against enterotoxigenic <i>Escherichia coli</i>. [PDF]

Front Immunol
Li H, Yang Z, She Y, Xu C, Ding W.
europepmc   +1 more source

Rationale for Recommending Varicella Vaccination Into the Swedish National Immunisation Programme

Acta Paediatrica, EarlyView.
ABSTRACT Aim Under Swedish law, a vaccination may be included in the National Immunisation Programme (NIP) if it effectively prevents transmission in the population, is cost‐effective and aligns with ethical and humanitarian principles. The Public Health Agency of Sweden (PHAS) evaluated these criteria for introducing varicella vaccination. Methods The
Annika Ersson, Kari Johansen, Sören Andersson   +2 more
wiley   +1 more source

CLINICO–Demographic Profile and Outcomes of Hospitalised Children With Diphtheria in A Tertiary Care Hospital of Peshawar

Acta Paediatrica, EarlyView.
ABSTRACT Aim To determine the clinico‐demographic profile and predictors of mortality in hospitalised children with diphtheria. Methods This retrospective cohort study included 202 children aged 5–16 years diagnosed with diphtheria per WHO criteria at Lady Reading Hospital, Peshawar, from January 2023 to December 2024. Data on demographics, vaccination
Amir Muhammad, Ashfaq Ahmed, Waqas Naseem, Ale Azad Othman, Mohsin Hassan, Lyaba Atta, Muhammad Tahir   +6 more
wiley   +1 more source

Multi-Antigen Protein Vaccine Confers Protection in a Murine Model Against Intranasal <i>Haemophilus influenzae</i> Challenge. [PDF]

Vaccines (Basel)
Belkacem N, Deghmane AE, Taha MK.
europepmc   +1 more source

A Novel Vitamin E Adjuvanted Injectable <i>Bordetella bronchiseptica</i> Vaccine Is Safe and Efficacious in Dogs. [PDF]

Vaccines (Basel)
Bruton B, Wouters PAWM, Tarpey I, Pearce J.   +3 more
europepmc   +1 more source

Understanding the Epidemiology of Pertussis in Denmark

Acta Paediatrica, EarlyView.
Tine Dalby, Aoife Ronayne, Peter Henrik Andersen   +2 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Understanding the High Incidence of Pertussis in Norway: The Role of Test Activity

Acta Paediatrica, EarlyView.
Margrethe Greve‐Isdahl, Elina Seppälä   +1 more
wiley   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source